Nothing Special   »   [go: up one dir, main page]

AR113890A1 - Preparado farmacéutico con excelentes propiedades de estabilidad a la luz y disolución - Google Patents

Preparado farmacéutico con excelentes propiedades de estabilidad a la luz y disolución

Info

Publication number
AR113890A1
AR113890A1 ARP180103378A ARP180103378A AR113890A1 AR 113890 A1 AR113890 A1 AR 113890A1 AR P180103378 A ARP180103378 A AR P180103378A AR P180103378 A ARP180103378 A AR P180103378A AR 113890 A1 AR113890 A1 AR 113890A1
Authority
AR
Argentina
Prior art keywords
light
dissolution
stability
pharmaceutical preparation
excellent properties
Prior art date
Application number
ARP180103378A
Other languages
English (en)
Inventor
Shohei Aikawa
Masato Gomi
Naomi Hayashi
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of AR113890A1 publication Critical patent/AR113890A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/802—Preparations for artificial teeth, for filling teeth or for capping teeth comprising ceramics
    • A61K6/813—Preparations for artificial teeth, for filling teeth or for capping teeth comprising ceramics comprising iron oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Ceramic Engineering (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Testing Resistance To Weather, Investigating Materials By Mechanical Methods (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

Un preparado que se colorea mínimamente a través de irradiación de luz con el recubrimiento de un preparado que contiene un compuesto representado por la fórmula (1) o una sal de este aceptable desde el punto de vista farmacéutico, o un cristal de este con una sustancia estabilizante a la luz y un polímero, en particular, con uno o más de óxido de titanio y talco usados como la sustancia estabilizante a la luz e hipromelosa usada como el polímero.
ARP180103378A 2017-11-17 2018-11-16 Preparado farmacéutico con excelentes propiedades de estabilidad a la luz y disolución AR113890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017222068 2017-11-17

Publications (1)

Publication Number Publication Date
AR113890A1 true AR113890A1 (es) 2020-06-24

Family

ID=66540251

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103378A AR113890A1 (es) 2017-11-17 2018-11-16 Preparado farmacéutico con excelentes propiedades de estabilidad a la luz y disolución

Country Status (13)

Country Link
US (1) US12064438B2 (es)
EP (1) EP3711767A4 (es)
JP (2) JP6660644B2 (es)
KR (1) KR102562514B1 (es)
CN (1) CN111615390A (es)
AR (1) AR113890A1 (es)
AU (1) AU2018369241B2 (es)
BR (1) BR112020009634B1 (es)
CA (1) CA3082522A1 (es)
IL (1) IL274625B (es)
MX (1) MX2020004680A (es)
TW (1) TWI795462B (es)
WO (1) WO2019098259A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020011130A (es) * 2018-04-24 2022-09-09 Shionogi & Co Forma de dosificacion solida que tiene excelente estabilidad.
CN112236146A (zh) * 2018-04-24 2021-01-15 盐野义制药株式会社 稳定性优良的固体制剂
US20220008429A2 (en) * 2019-03-22 2022-01-13 Shionogi & Co., Ltd. Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a severe influenza condition
EP3714889A1 (en) * 2019-03-29 2020-09-30 F. Hoffmann-La Roche AG Baloxavir for the prevention of transmission of influenza virus
WO2021038480A1 (en) * 2019-08-27 2021-03-04 Janssen Pharmaceuticals, Inc. Combinations for treating influenza virus
WO2021084725A1 (ja) * 2019-10-31 2021-05-06 フジデノロ株式会社 検出装置、磁気組成物、及び、管理システム
CN111647005A (zh) * 2020-06-15 2020-09-11 安徽皓元药业有限公司 巴洛沙韦新晶型及其制备方法
JP7557863B2 (ja) 2020-10-12 2024-09-30 共和薬品工業株式会社 イストラデフィリン含有医薬組成物
CN112730682B (zh) * 2020-12-25 2022-06-17 苏州海科医药技术有限公司 一种抗病毒药物临床研究血浆样本中奥司他韦及代谢物奥司他韦酸浓度的生物分析方法
CN114306261A (zh) * 2021-12-15 2022-04-12 澳美制药(苏州)有限公司 巴洛沙韦酯片及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759293B1 (fr) 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
DE19831869A1 (de) * 1998-07-16 2000-01-20 Merck Patent Gmbh Farbgebung mit Perlglanzpigmenten im Lebensmittel- und Pharmabereich
EP1356816B1 (en) 2001-01-29 2009-12-23 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
EP1460062A4 (en) * 2001-12-28 2005-12-14 Takeda Pharmaceutical NITROGEN-CONTAINING CYCLIC KETONE DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF
SE0203778D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
ZA200803655B (en) 2005-10-31 2009-10-28 Kowa Co Pharmaceutical preparation having excellent photostability
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
JP2008201712A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd フィルムコーティング製剤
JPWO2008114859A1 (ja) * 2007-03-22 2010-07-08 アステラス製薬株式会社 ピラゾール誘導体を含有する医薬組成物
KR101700267B1 (ko) 2008-07-25 2017-01-26 비이브 헬쓰케어 컴퍼니 화합물
JP5644167B2 (ja) 2009-04-21 2014-12-24 大正製薬株式会社 溶出改善されたケトチフェン又はその塩を含有する固形製剤
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
MX2012001660A (es) * 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
US20120009259A1 (en) * 2010-07-06 2012-01-12 Urbain Alfons Clementina Delaet Formulation for co-therapy treatment of diabetes
JP4803686B2 (ja) * 2010-08-31 2011-10-26 協和発酵キリン株式会社 苦味を呈する薬物を含有する顆粒および口腔内崩壊錠
KR101841087B1 (ko) 2011-04-22 2018-03-23 아스텔라스세이야쿠 가부시키가이샤 고형 의약 조성물
RU2602911C2 (ru) * 2011-05-20 2016-11-20 Астразенека Юкей Лимитед Фармацевтическая композиция, содержащая кальциевую соль розувастатина
BR112014007753B1 (pt) * 2011-09-30 2021-07-06 Astellas Pharma Inc. composição farmacêutica granular, formulação e método para produção
KR101943686B1 (ko) 2012-04-24 2019-01-29 다이이찌 산쿄 가부시키가이샤 구강내 붕괴정 및 그 제조 방법
JP2015054822A (ja) * 2013-09-10 2015-03-23 ニプロ株式会社 クロピドグレル含有錠剤およびその製造方法
JP2015054851A (ja) * 2013-09-13 2015-03-23 大鵬薬品工業株式会社 被覆経口固形製剤
EP3068435A1 (en) * 2013-11-13 2016-09-21 Novartis AG Mtor inhibitors for enhancing the immune response
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
CR20170530A (es) * 2015-04-28 2018-01-25 Shionogi & Co Derivados de piridona policíclica sustituída y profármaco de los mismos.
JP6516840B2 (ja) * 2015-06-18 2019-05-22 共同印刷株式会社 ブリスターパック用積層体、及びそれを用いたブリスターパック
PE20181516A1 (es) * 2015-12-15 2018-09-21 Shionogi & Co Medicamento para tratar la gripe caracterizado por combinar un inhibidor de endonucleasa dependiente de cap y un farmaco antigripal
CN112236146A (zh) 2018-04-24 2021-01-15 盐野义制药株式会社 稳定性优良的固体制剂

Also Published As

Publication number Publication date
US12064438B2 (en) 2024-08-20
EP3711767A4 (en) 2021-12-01
US20200375998A1 (en) 2020-12-03
IL274625B (en) 2022-08-01
EP3711767A1 (en) 2020-09-23
KR20200089290A (ko) 2020-07-24
CA3082522A1 (en) 2019-05-23
BR112020009634B1 (pt) 2022-08-30
WO2019098259A1 (ja) 2019-05-23
AU2018369241A1 (en) 2020-06-18
JP2020079283A (ja) 2020-05-28
TWI795462B (zh) 2023-03-11
TW201922259A (zh) 2019-06-16
JP7251891B2 (ja) 2023-04-04
IL274625A (en) 2020-06-30
BR112020009634A2 (pt) 2020-11-10
MX2020004680A (es) 2020-08-13
JP6660644B2 (ja) 2020-03-11
AU2018369241B2 (en) 2023-01-05
JPWO2019098259A1 (ja) 2019-12-12
KR102562514B1 (ko) 2023-08-03
CN111615390A (zh) 2020-09-01

Similar Documents

Publication Publication Date Title
AR113890A1 (es) Preparado farmacéutico con excelentes propiedades de estabilidad a la luz y disolución
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CO2019008487A2 (es) Compuesto de quinazolina
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
BR112018071585A2 (pt) formulações de um inibidor de lsd1
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CO2018011935A2 (es) Derivados aromáticos de sulfonamida
CL2016001364A1 (es) Moduladores de ror gamma (rory)
PE20180160A1 (es) Sulfonilureas y compuestos relacionados y uso de estos
CY1123479T1 (el) Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
AR111315A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR099854A1 (es) Derivados de quinaxolina con acción sobre tirosinquinasas
AR106025A1 (es) Formas cristalinas de ácido siálico o una sal o solvato de este
AR111878A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR095034A1 (es) El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares
CY1124493T1 (el) Υγρη φαρμακευτικη συνθεση
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
CY1122352T1 (el) Φαρμακευτικη συνθεση περιεχοντας μιραβεγρονη
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
PH12018500377A1 (en) Novel annelated benzamides
DOP2018000190A (es) Nueva forma cristalina de sal de 1–(5–(2,4–difluorfenil)–1–((3–fluorfenil)sulfonil)–4–metoxi–1h–pirrol–3–il)–n–metilmetanamina